Role of statins in diabetes complications

Current Diabetes Reviews

Volumn 5, Issue 3, 2009, Pages 165-170

  Martin, Jennifer H ^a,b   Mangiafico, Salvatore ^b   Kelly, Darren J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; CERIVASTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; QUINAPRIL; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROSIGLITAZONE; SIMVASTATIN; STREPTOZOCIN; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL TRIAL; CONCENTRATION RESPONSE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART DEATH; HEART DISEASE; HEART VENTRICLE FIBRILLATION; HUMAN; INFLAMMATION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; TUBULOINTERSTITIAL FIBROSIS; ANIMAL; CARDIOVASCULAR DISEASE; DISEASE MODEL; FIBROSIS; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MOUSE; RAT;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY DISEASES; MICE; RATS;

EID: 70349783923     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909788920901     Document Type: Review

References (43)

1. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Group. HPSC. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005-2016
2. Ludwig S, Shen G. Statins for diabetic cardiovascular complications. Curr Vasc Pharmacol 2006; 4(3): 245-251
3. Knopp R, d'Emden M, Smilde J, Pocock S. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29(7): 1478-1485
4. Christopher P, Cannon M, Braunwald E, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-1504 (Pubitemid 38477774)
5. Colhoun H, Betteridge D, Durrington P, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696 (Pubitemid 39140624)
6. Keech A, Simes R, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-1861.
7. Kastelein J, Akdim F, Stroes E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443
8. Kanter J, Averill M, Leboeuf R, Bornfeldt K. Diabetes-accelerated atherosclerosis and inflammation. Circ Res 2008; 103(8): e116-7.
9. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203(2): 325-330
10. Mozaffarian D, Minami E, Letterer R, Lawler R, McDonald G, Levy W. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005; 96(12): 1699-1704 (Pubitemid 41790394)
11. Krysiak R, Okopień B. Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep 2008; 60(4): 514-523
12. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362 (Pubitemid 32105973)
13. Abuissa H, Jones P, Marso S, O'Keefe J. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46(5): 821-826 (Pubitemid 41224805)
14. Sever P, Poulter N, Dahlof B, Wedel H, Collins R, Beevers G. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28(5): 1151-1157 (Pubitemid 40616627)
15. Deans K, Sattar N. "Anti-inflammatory" drugs and their effects on type 2 diabetes. Diabetes Technol Ther 2006; 8(1): 18-27.
16. Haidara M, Yassin H, Ammar H, Rateb M, Zorkani M. Role of oxidative stress in cardiovascular complication in diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-227 (Pubitemid 46785489)
17. Buttke T, Sandstorm P. Oxidative stress as a mediator of apoptosis. Immunol Today 1994; 15: 7-10.
18. Siddals K, Marshman E, Westwood M, Gibson J. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 2004; 279(37): 38353-38359 (Pubitemid 39295984)
19. Vecchione C, Gentile M, Aretini A, et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia 2007; 50(4): 874-880 (Pubitemid 46355833)
20. Kakafika A, Liberopoulos E, Karagiannis A, Athyros V, Mikhailidis D. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol 2006; 4(3): 175-183
21. Wang L, Rockwood J, Zak D, Devaraj S, Jialal I. Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Metab Syndr Relat Disord 2008; 6(2): 149-152 (Pubitemid 351769262)
22. Ludwig S, Dharmalingam S, Erickson-Nesmith S, et al. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 70(2): 110-118 (Pubitemid 41368058)
23. Dalla Nora E, Passaro A, Zamboni P, Calzoni F, Fellin R, Solini A. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest 2003; 26(1): 73-78 (Pubitemid 36292256)
24. Tawfik H, El-Remessy A, Matragoon S, Ma G, Caldwell R, Caldwell R. Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 2006; 319(1): 386-395 (Pubitemid 44455146)
25. Cakmak A, Yemisci M, Koksoy C, Yazgan U, Dincer D, Dalkara T. Statin Pre-treatment protects brain against focal cerebral ischemia in diabetic mice. J Surg Res 2007; 138(2): 254-258 (Pubitemid 46365720)
26. Fujii T, Onimaru M, Yonemitsu Y, Kuwano H, Sueishi K. Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression. Am J Physiol Heart Circ Physiol 2008; 294(6): H2785-91.
27. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008; 107(1): 80-89 (Pubitemid 351744086)
28. Danesh FMS, Amro N, Philips C, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002; 99(12): 8301-8305
29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352(9131): 837-853 (Pubitemid 28416718)
30. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103(3): 357-362 (Pubitemid 32105973)
31. Sabatine M, Wiviott S, Morrow D, McCabe C, Cannon C. High Dose Atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 Substudy (abstract). Circulation 2004; 110(Suppl): I-834.
32. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13: 95-100.
33. Yu Y, Ohmori K, Chen Y. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44: 904-913 (Pubitemid 39099592)
34. Wong V, Stavar L, Szeto L, Uffelman K, Wang C, Fantus I. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006; 184: 348-355 (Pubitemid 43049719)
35. Jinnouchi Y, Yamagishi S, Takeuchi M, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006; 6(4): 191-193 (Pubitemid 46025593)
36. Cuccurullo C, Iezzi A, Fazia M, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26(12): 2716-2723 (Pubitemid 44777287)
37. Adameova A, Kuzelova M, Faberova V, Svec P. Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats. Pharmazie 2006; 61(9): 807-808 (Pubitemid 44450377)
38. Tekin G, Tekin A, Canatar T, et al. Simvastatin improves the attenuated heart rate recovery of type 2 diabetics. Pharmacol Res 2006; 54(6): 442-446 (Pubitemid 46053820)
39. Kelly D, Wilkinson-Berka J, Gilbert R. Progressive diabetic nephropathy in the Ren-2 rat. Am J Physiol Renal Physiol 2007; 292(2): F820-7.
40. Mangiafico S, Kelly D. Effects of an ACE inhibitor and a statin on renal fibrosis in diabetes. Thesis, Department of Medicine, University of Melbourne, Australia 2006.
41. Bohle A, Wehrmann M, Bogenschultz O, Batz C, Muller C, Muller G. The pathogenesis of chronic renal failure in diabetic nephropathy: Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187: 251-259
42. Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008; 74(11): 1461-1467
43. Strippoli G, Navaneethan S, Johnson D, Pellegrini F, Nicolucci A, Craig J. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336(7645): 645-651